Diadema Partners LP Pacira Bio Sciences, Inc. Transaction History
Diadema Partners LP
- $383 Billion
- Q1 2025
A detailed history of Diadema Partners LP transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 38,926 shares of PCRX stock, worth $996,505. This represents 0.25% of its overall portfolio holdings.
Number of Shares
38,926Holding current value
$996,505% of portfolio
0.25%Shares
1 transactions
Others Institutions Holding PCRX
# of Institutions
255Shares Held
50.5MCall Options Held
157KPut Options Held
139K-
Black Rock Inc. New York, NY8.01MShares$205 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.24MShares$134 Million0.0% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY2.26MShares$58 Million0.06% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.24MShares$57.4 Million0.09% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.05MShares$52.5 Million0.01% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.17B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...